Cervical cancer: what is the optimal age for routine testing?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11310%2F15%3A10294929" target="_blank" >RIV/00216208:11310/15:10294929 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/15:10294929 RIV/00064203:_____/15:10294929 RIV/00023736:_____/15:00011296

Výsledek na webu

<a href="http://dx.doi.org/10.2217/fon.15.42" target="_blank" >http://dx.doi.org/10.2217/fon.15.42</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2217/fon.15.42" target="_blank" >10.2217/fon.15.42</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cervical cancer: what is the optimal age for routine testing?

Popis výsledku v původním jazyce

Carcinoma of the uterine cervix is the fourth most common malignant tumor in women worldwide. It is estimated that in 2012 there will be 528,000 new cases and 266,000 deaths in the world. A large majority of the global burden occurs in developing countries, where 445,000 cases and 230,000 deaths from cervical cancer take place annually. The high incidence and mortality rates of invasive cervical cancer (ICC) in less developed regions have a variety of causes, such as economic obstacles and the unavailability of infrastructure, which are necessary to facilitate screening, diagnosis and treatment. In the long run an effective way to reduce the incidence and mortality in developing countries would be to institute an extensive vaccination program before the onset of sexual activity with technical and economic support from developed countries. The development of an infrastructure that provides effective screening, diagnosis and treatment of precancerous lesions and early cancer stages is un

Název v anglickém jazyce

Cervical cancer: what is the optimal age for routine testing?

Popis výsledku anglicky

Carcinoma of the uterine cervix is the fourth most common malignant tumor in women worldwide. It is estimated that in 2012 there will be 528,000 new cases and 266,000 deaths in the world. A large majority of the global burden occurs in developing countries, where 445,000 cases and 230,000 deaths from cervical cancer take place annually. The high incidence and mortality rates of invasive cervical cancer (ICC) in less developed regions have a variety of causes, such as economic obstacles and the unavailability of infrastructure, which are necessary to facilitate screening, diagnosis and treatment. In the long run an effective way to reduce the incidence and mortality in developing countries would be to institute an extensive vaccination program before the onset of sexual activity with technical and economic support from developed countries. The development of an infrastructure that provides effective screening, diagnosis and treatment of precancerous lesions and early cancer stages is un

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Future Oncology

ISSN

1479-6694

e-ISSN

—

Svazek periodika

11

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

4

Strana od-do

1137-1140

Kód UT WoS článku

000352512900001

EID výsledku v databázi Scopus

2-s2.0-84926429624